Home > Insider Trading > Filing (0000921895-22-002404)

Filing Details

Accession Number:: 0000921895-22-002404
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-08-11 17:52:51
Reporting Period:: 2022-08-09

Accepted Time:: 2022-08-11 17:52:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
891293	Cti Biopharma Corp	CTIC	Pharmaceutical Preparations (2834)	911533912

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
918923	P L Fund Value Biotechnology	44 Montgomery St. 40Th Fl San Francisco CA 94104	Yes	No	Yes	Yes
1055947	P/Il L Partners Bvf	44 Montgomery St. 40Th Fl San Francisco CA 94104	Yes	No	Yes	Yes
1056807	Bvf Inc/Il	44 Montgomery St. 40Th Fl San Francisco CA 94104	Yes	No	Yes	Yes
1102444	Biotechnology Value Fund Ii Lp	44 Montgomery St. 40Th Fl San Francisco CA 94104	Yes	No	No	Yes
1233840	N Mark Lampert	44 Montgomery St. 40Th Fl San Francisco CA 94104	Yes	No	Yes	Yes
1660683	Biotechnology Value Trading Fund Os Lp	P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104	Yes	No	No	Yes
1660684	Ltd. Os Partners Bvf	P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104	Yes	No	No	Yes
1803805	Bvf I Gp Llc	44 Montgomery St., 40Th Floor San Francisco CA 94104	Yes	No	Yes	Yes
1803806	Bvf Ii Gp Llc	44 Montgomery St., 40Th Floor San Francisco CA 94104	Yes	No	No	Yes
1803809	Bvf Gp Holdings Llc	44 Montgomery St., 40Th Floor San Francisco CA 94104	Yes	No	Yes	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001	Disposition	2022-08-09	3,850,803	$6.12	235,130	No	4	S	Direct
Common Stock, Par Value $0.001	Acquisiton	2022-08-09	3,754,000	$0.00	3,989,130	No	4	C	Direct
Common Stock, Par Value $0.001	Disposition	2022-08-09	2,890,723	$6.12	168,573	No	4	S	Direct
Common Stock, Par Value $0.001	Acquisiton	2022-08-09	2,426,666	$0.00	2,595,239	No	4	C	Direct
Common Stock, Par Value $0.001	Disposition	2022-08-09	469,040	$6.12	19,839	No	4	S	Direct
Common Stock, Par Value $0.001	Acquisiton	2022-08-09	682,666	$0.00	702,505	No	4	C	Direct
Common Stock, Par Value $0.001	Disposition	2022-08-09	1,289,434	$6.12	6,148	No	4	S	Indirect	See footnote
Common Stock, Par Value $0.001	Acquisiton	2022-08-09	1,519,999	$0.00	1,526,147	No	4	C	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	C	Direct
No	4	S	Direct
No	4	C	Direct
No	4	S	Direct
No	4	C	Direct
No	4	S	Indirect	See footnote
No	4	C	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.001	Series O Convertible Preferred Stock	Disposition	2022-08-09	5,631	$0.00	3,754,000	$0.00
Common Stock, Par Value $0.001	Series O Convertible Preferred Stock	Disposition	2022-08-09	3,640	$0.00	2,426,666	$0.00
Common Stock, Par Value $0.001	Series O Convertible Preferred Stock	Disposition	2022-08-09	1,024	$0.00	682,666	$0.00
Common Stock, Par Value $0.001	Series O Convertible Preferred Stock	Disposition	2022-08-09	2,280	$0.00	1,519,999	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.001	43,139	Indirect	See footnote

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock, Par Value $0.001	Series X Convertible Preferred Stock	$10,000.00		15,940,000	1,594	Direct
Common Stock, Par Value $0.001	Series X Convertible Preferred Stock	$10,000.00		12,500,000	1,250	Direct
Common Stock, Par Value $0.001	Series X Convertible Preferred Stock	$10,000.00		1,910,000	191	Direct
Common Stock, Par Value $0.001	Series X Convertible Preferred Stock	$10,000.00		120,000	12	Indirect
Common Stock, Par Value $0.001	Series X1 Convertible Preferred Stock	$0.00		3,440,000	344	Direct
Common Stock, Par Value $0.001	Series X1 Convertible Preferred Stock	$0.00		2,390,000	239	Direct
Common Stock, Par Value $0.001	Series X1 Convertible Preferred Stock	$0.00		170,000	17	Direct
Common Stock, Par Value $0.001	Non-Qualified Stock Option (Right to Buy)	$0.84	2029-05-16	120,000	120,000	Indirect
Common Stock, Par Value $0.001	Non-Qualified Stock Option (Right to Buy)	$4.61	2028-05-17	60,000	60,000	Indirect
Common Stock, Par Value $0.001	Stock Option (Right to Buy)	$4.25	2027-02-22	50,000	50,000	Indirect
Common Stock, Par Value $0.001	Stock Option (Right to Buy)	$3.30	2031-03-10	80,000	80,000	Indirect
Common Stock, Par Value $0.001	Stock Option (Right to Buy)	$4.49	2032-03-09	80,000	80,000	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
	15,940,000	1,594	Direct
	12,500,000	1,250	Direct
	1,910,000	191	Direct
	120,000	12	Indirect
	3,440,000	344	Direct
	2,390,000	239	Direct
	170,000	17	Direct
2029-05-16	120,000	120,000	Indirect
2028-05-17	60,000	60,000	Indirect
2027-02-22	50,000	50,000	Indirect
2031-03-10	80,000	80,000	Indirect
2032-03-09	80,000	80,000	Indirect

Footnotes

This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock, par value $0.001 (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
Securities held in certain Partners managed accounts (the "Partners Managed Accounts"). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts.
Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Mr. Perry, who serves on the Issuer's Board of Directors and as a member of Partners, pursuant to which Mr. Perry is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Perry disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
The Series O Convertible Preferred Stock, par value $0.001 per share (the "Series O Preferred Stock") has no expiration date and is convertible at any time at the option of the holder thereof. Each share of Series O Preferred Stock is convertible into the number of shares of Common Stock equal to a Conversion Ratio equal to a Stated Value of $2,000 per share divided by a Conversion Price of $3.00, or approximately 667 shares of Common Stock for each share of Series O Preferred Stock. The Series O Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion.
The exercise of the Series O Preferred Stock and the corresponding acquisition of the underlying shares of Common Stock reported herein are exempt from Section 16 pursuant to Rule 16b-3, Rule 16b-6 or otherwise.
Shares of Series X Preferred Stock acquired pursuant to the terms and conditions of a backstop commitment made by certain of the Reporting Persons in connection with the Issuer's rights offering.
The Series X Convertible Preferred Stock, par value $0.001 per share (the "Series X Preferred Stock") has no expiration date, and is convertible into shares of Common Stock at any time at the option of the holder thereof. Each share of Series X Preferred Stock is convertible into 10,000 shares of Common Stock. The Series X Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion.
The Series X1 Convertible Preferred Stock, par value $0.001 per share (the "Series X1 Preferred Stock") has no expiration date, and is convertible into shares of Common Stock at any time at the option of the holder thereof. Each share of Series X1 Preferred Stock is convertible into 10,000 shares of Common Stock. The Series X1 Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion.
This stock option has vested in its entirety in accordance with its terms.
This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Issuer's stockholders in 2023 at which one or more members of the Issuer's Board of Directors are to be elected, subject to Mr. Perry's continued service through such date or event.